Cambridge biopharma hires top gun for new CMO position
F-star, the Cambridge-based cancer pioneer, has appointed Louis Kayitalire, MD, as chief medical officer.
F-star believes this newly created management position will be crucial to its transition to a wholly-owned portfolio strategy as it expands its clinical operation capabilities and accelerates progression of its proprietary pipeline.
The Babraham Research Campus-based clinical-stage biopharma company is delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.
Dr Kayitalire will oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody currently in a Phase 1 clinical trial, recruiting the expansion cohorts of the two highest dose levels.
He will also lead the clinical strategy and operations for F-star’s pipeline of potential first and best-in-class immuno-oncology bispecific antibody therapeutics, including FS120 and FS222, two proprietary product candidates currently in cGMP production and on track for investigational new drug application submissions this year.
Dr Kayitalire said: “As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never been greater. I believe F-star is ideally positioned to become the next leader in this field.”
Dr Kayitalire brings over 20 years’ experience in oncology and immuno-oncology, having previously held positions at major pharmaceutical companies including Bristol-Myers Squibb, Celgene and Eli Lilly.
He has strong commercial acumen to complement his extensive clinical expertise with a proven track record of developing and delivering clinical research programmes and ensuring alignment with overall medical and commercial strategies.